** Scientific tools maker Akoya Biosciences' AKYA.O shares fall 21.1% to $2.47 premarket
** On Thursday, co forecast 2024 rev. between $80 mln and $85 mln, lower than prior range of $96 mln to $104 mln
** Co makes products used by academics and biotechs to detect and map cell types and biomarkers, to help them understand patient response to therapy
** Since 2023, high interest rates have forced biotech companies, clients of life science firms, to cut spending
** Co posted Q3 sales of $18.8 mln, missing avg analysts' est. of $25.4 mln - LSEG
** As of last close, stock has fallen ~36% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。